← All Argenx SE filings

Argenx SE 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
ARGX
Argenx SE
20-F: argenx SE Reports Strong 2025 with $4.2B Sales, Pipeline Advances
argenx SE achieved significant operational and financial milestones in 2025, including record product net sales of $4.2 billion and substantial progress across its immunology pipeline.
NASDAQ
ARGX
Argenx SE
20-F: Argenx SE Files 20-F Report, Highlights Commercial Growth and Pipeline Advancement
Argenx SE's 20-F filing showcases the company's commercial expansion with VYVGART and VYVGART HYTRULO, alongside progress in its pipeline development.
NASDAQ
ARGX
Argenx SE
20-F: Argenx Unveils 2023 Equity Incentive Plan to Align Employee Interests with Long-Term Growth
Argenx introduces a new equity incentive plan in 2023, offering stock options and restricted stock units (RSUs) to key personnel to foster long-term commitment and align their interests with the company's success.